Mental Health Clinics in Rockledge, FL Accepting Medicare
50 Mental Health Clinics found. Showing 41 - 50
 Behavior Services Of Brevard County Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 550 Solutions Way, Rockledge, FL 32955 Phone: 321-739-9800 |
Alan P. Smith Counseling Services Social Worker - Clinical Medicare: Medicare Enrolled Practice Location: 2588 Addington Cir, Rockledge, FL 32955 Phone: 321-757-4030 Fax: 321-369-9836 |
Be Inspired Counseling Services Inc Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 881 Barton Blvd Ste 8, Rockledge, FL 32955 Phone: 321-301-0180 |
Allies In Wellness, Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 391 Commerce Pkwy Ste 220, Rockledge, FL 32955 Phone: 321-258-9537 |
Kaleidoscope Interventions Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 5830 Us Highway 1 Ste 104, Rockledge, FL 32955 Phone: 321-609-9007 |
Crescent Coast Neurology, L.l.c. Psychiatry & Neurology - Neurology Medicare: Medicare Enrolled Practice Location: 1910 Rockledge Blvd Ste 101, Rockledge, FL 32955 Phone: 321-636-8366 Fax: 321-636-3985 |
Family Counseling Center Of Brevard, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 840 Brevard Ave, Rockledge, FL 32955 Phone: 321-632-5792 Fax: 321-632-5796 |
Behavior Works Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 759 White Pine Ave, Rockledge, FL 32955 Phone: 321-543-6729 Fax: 321-631-3400 |
Anne Craig Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 1019 Harvin Way, Suite 110, Rockledge, FL 32955 Phone: 321-633-9333 Fax: 321-633-9334 |
Live Inspired Counseling & Support Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 4908 Sprint Cir, Rockledge, FL 32955 Phone: 321-294-3211 |
News Archive
Quest Diagnostics hosts series of "Tech Talks" and programs during HIMSS 2014
Quest Diagnostics, the world's leading provider of diagnostic information services, will exhibit at booth 3064 and host a series of "Tech Talks" and other programs during the HIMSS 2014 Annual Conference & Exhibition, the industry's largest health IT educational program and exhibition February 23 – 27 in Orlando, Florida.
Health care process found to be challenging for adolescents with autism and their caregivers
For most people, trips to the doctor can be quite scary. For adolescents and young adults with autism, taking control of health care decisions is not only frightening, it also can be a barrier to independence.
Akela reports total consolidated revenues of $4.2 million for three months ended March 31, 2011
Akela Pharma, Inc., a drug development company with its lead product, Fentanyl TAIFUN, being developed for the treatment of breakthrough cancer pain and the company's wholly owned subsidiary, PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three months and year ended March 31, 2011.
Exciting progress made in MS research during 2010
Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).
Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
› Verified 7 days ago